Crinetics Pharmaceuticals’ Post

Our September NCATS newsletter is out! Learn about: ▪️ a potential new treatment for #ParkinsonsDisease and how #3D models of the brain tested an antiviral drug to uncover it ▪️ how #N3C delivers insight into #LongCOVID revealing the best time to predict infection ▪️ a new form of ketamine that could treat depression and pain Read it today! https://lnkd.in/e9QYPmhP

Gastric and small intestinal motor dysfunction may be an important contributor to the development of proton pump inhibitor (PPI)-refractory esophagitis in patients with systemic sclerosis. In addition to treatment with PPl, concomitant treatment with prokinetic agents could be advisable in these patients. 🔗https://lnkd.in/dFJjtjbY

Transfusional iron overload (TIO) results from chronic #bloodtransfusions administered for a range of conditions such as #thalassaemia, #sicklecell disease, and #myelodysplasia. This overload manifests as excessive iron accumulation in vital organs such as the #heart, #liver, #pancreas, and #thyroid, which can lead to significant organ damage unless properly managed with #ironchelation therapies (ICT). A novel medicine, SP-420, is currently being tested in a Phase II #clinicaltrial (THAL-01) as a potential #treatment for iron overload in adult #patients with transfusion-dependent ß-thalassaemia. This new medication is designed to deliver high levels of drug directly to critical organs affected by #ironoverload. SP-420 is expected to offer a safer and more effective alternative to current treatments with advantages such as increased #tolerance and oral #bioavailability. For more information on SP-420 and the THAL-01 trial, visit: https://lnkd.in/dbY_U8Q5

NEW STUDY - C-19 products associated with acquired hemophilia A (AHA), a rare autoimmune disorder that causes impaired blood clotting and spontaneous bleeding. A 56-year-old Korean man developed AHA 2 weeks following the second dose of a Pfizer product. He presented with a large 20 × 30 cm-sized hematoma along the psoas muscle and intracranial hemorrhage, necessitating intensive care with mechanical ventilation and continuous renal replacement therapy. Despite the treatments, the patient developed sepsis and died 14 weeks after admission. "AHA should be considered in the differential diagnosis of unusual bleeding following the vacc..." https://lnkd.in/g9KGDyeU #MFScholar

From the #Transfusion Evidence Alert: Efficacy and safety of immunosuppressive therapy combined with #eltrombopag for severe aplastic anemia:  a #systematicreview and #metaanalysis by Zhang et al. https://lnkd.in/esgrEbjh

Even though the investigators could not account for preexisting kidney function or the effects of co-administered drugs, this information is useful for immuno-oncology (IO) clinical trials. With respect to specific drugs, the riskiest drugs for Acute Kidney Injury (AKI) among conventional cytotoxic therapy agents included pentostatin, ixabepilone, and trabectedin. Among targeted therapies, olaratumab, itacitinib, mobecertinib, and duvelisib carried the highest risks. Among immunotherapies, aldesleukin, a recombinant form of human interleukin-2, and chimeric antigen receptor (CAR) T cell therapy drugs such as idecabtagene vicleucal, brexucabtagene autoleucel, and tisagenlecleucel were disproportionality associated with kidney-related outcomes. Additionally, PD-1 inhibitors such as dostarlimab and CTLA-4 inhibitors such as tremelimumab were associated with AKI. Tubulointerstitial Nephritis (TIN) was mostly associated with immunotherapies, especially tremelimumab, cemiplimab, pembrolizumab, nivolumab, blinatumomab, and ipilimumab. Carmustine, a cytotoxic therapy, as well as copanlisib, a targeted therapy, were also strongly associated.

Rates of acute kidney injury and tubulointerstitial nephritis associated with anticancer therapy have increased worldwide since 2010, attributable mainly to targeted therapies and immunotherapies. https://lnkd.in/gc7XHVyz

😊 Te invitamos a leer "Comparative evaluation of hydrogen peroxide and Chlorhexidine mouthwash on salivary interleukin-1ß levels in patients with type 2 diabetes mellitus and chronic periodontitis: a randomized controlled clinical trial", https://lnkd.in/eWzshYt3

"Pentoxifylline Emerges as a Therapeutic Beacon in Mitigating Kidney Ischemia/Reperfusion Injury: Unveiling the Novel Implications of Galectin-3 and ASK-1/JNK & ERK1/2/NF-κB/HMGB-1 Trajectories. A Precision Symphony in Renal Protection! 🌐🔬 #ScientificBreakthrough #KidneyHealth #PentoxifyllineAdvancements"

Early use of #lenalidomide can delay onset of transfusion dependency and improve tx response in pts who have non-transfusion-dependent #myelodysplasticsyndrome with #chromosome5q deletion, according to findings from a phase III trial:  #MDS, #Heme  https://lnkd.in/eWjNvu2C